KEDPLASMA

KEDPlasma currently operates twelve plasma collection centers in the United States, four centers in Germany and three centers in Hungary, with all centers having approval by European authorities and/or the US Food and Drug Administration. The company's collection center in Buffalo, New York is specialized in collecting hyper-immune Anti-D human plasma for the manufacture of an Anti-D immunoglobulin pharmaceutical product for the prevention of hemolytic disease of the fetus and newborn (HDFN). State-of-the-art production facilities producing a wide range of products and an unwavering commitment to research and development are the key factors of Kedrion's success.